Removing B2m with Nanobodies
Among those on dialysis, a build up in the blood of Beta-2 microglobulin (B2m) is responsible for potentially crippling dialysis-related amyloidosis (DRA). Nanobodies are functional antibody fragments—and, used in a resin, they captured 17 times more B2m than in earlier studies, without affecting other blood proteins. Even better, the resin can be regenerated and used again. One day, this approach may be combined with dialysis to improve treatments.
Read the full article » | Posted 03-16-2020
Related Articles
- VenoStent, Inc. is Recruiting Patients for a Clinical Trial of the SelfWrap Posted 10-14-2025
- Diality Treated its First Patient in the Moda-flx Home IDE PRESCRIBE Cinical Trial Posted 10-14-2025
- eGenesis Announces IND Clearance for EGEN-2784 in Kidney Transplant Posted 09-15-2025
- The First Artificial Kidney Built in Canada has Ties to London: A Revolution in Care for Patients with Kidney Failure Posted 09-15-2025

